<DOC>
	<DOCNO>NCT00001695</DOCNO>
	<brief_summary>Simultaneous use alternative complementary medical therapy cancer patient undergoing conventional medical treatment extremely common may always disclose patient 's treating physician . Cancer patient undergo Phase I therapy clinical trial constitute special population patient , since definition , prescribe therapy scientifically unproven term efficacy . Phase I patient closely monitored adverse effect order identify characterize toxicity define tolerable dose experimental treatment . Thus , unrecognized use alternative therapy patient actively enrol phase I trial may potentially confound rational drug development cause adverse side effect contribute drug interaction . Examples clinical toxicity induce alternative medical treatment include liver dysfunction renal failure cause herbal preparation , hematologic abnormality , eosinophilia-myalgia syndrome cause tryptophan food supplement . Therefore , important document determine prevalence alternative therapy use specific patient population ; however , issue previously examine scientifically rigorous manner . We propose conduct survey interview study phase I cancer patient enrol ongoing clinical trial National Cancer Institute determine prevalence alternative therapy use population . This study also examine patient attitude perception regard use alternative therapy compare scientifically-sanctioned phase I experimental therapy . This information important implication drug development .</brief_summary>
	<brief_title>Survey Use Alternative Medical Therapies Adult Cancer Patients Enrolled Phase I Clinical Trials</brief_title>
	<detailed_description>Simultaneous use alternative complementary medical therapy cancer patient undergoing conventional medical treatment extremely common may always disclose patient 's treating physician . Cancer patient undergo Phase I therapy clinical trial constitute special population patient , since definition , prescribe therapy scientifically unproven term efficacy . Phase I patient closely monitored adverse effect order identify characterize toxicity define tolerable dose experimental treatment . Thus , unrecognized use alternative therapy patient actively enrol phase I trial may potentially confound rational drug development cause adverse side effect contribute drug interaction . Examples clinical toxicity induce alternative medical treatment include liver dysfunction renal failure cause herbal preparation , hematologic abnormality , eosinophilia-myalgia syndrome cause tryptophan food supplement . Therefore , important document determine prevalence alternative therapy use specific patient population ; however , issue previously examine scientifically rigorous manner . We propose conduct survey interview study phase I cancer patient enrol ongoing clinical trial National Cancer Institute determine prevalence alternative therapy use population . This study also examine patient attitude perception regard use alternative therapy compare scientifically-sanctioned phase I experimental therapy . This information important implication drug development .</detailed_description>
	<criteria>Patients must register actively participate Phase I clinical trial Division Hematology/Oncology , National Naval Medical Center . Patients must able give sign , informed consent . Patients must great equal 18 year old . Patients must medically well enough interview fill study questionnaire . Patients must previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Complementary Medicine</keyword>
	<keyword>Unproven Treatments</keyword>
	<keyword>Herbal</keyword>
</DOC>